 BNC210 for Treatment of Social Anxiety Disorder SAD Did Not Meet Primary Endpoint Subjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to Placebo BNC210 Demonstrated Favourable Safety and Tolerability Profile Consistent with Prior Experience Company is Continuing Analysis of the Data and Evaluating Next Steps with Cash Runway into ... The post Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorde... 